1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop repot Updated 2008. www. goldcopd.com Last accessed: June 2008.
2. Postma DS, Calverley P Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34 (1): 10–2.
3. Burge PS, Calverley PM, Jones PW et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–03.
4. Calverley PM, Anderson JA, Celli B et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–89.
5. Aaron SD, Vandemheen KL, Fergusson D et al. Tiotropium in Combination with Placebo, Salmeterol or Fluticasone-Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease. Ann Intern Med 2007; 146: 545–55.
6. Wedzicha JA, Calverley PMA, Seemungal TA et al. The Prevention of Chronic Obstructive Pulmonary Disease Exacerbations by Salmeterol/Fluticasone Propionate or Tiotropium Bromide. Am J Respir Crit Care Med 2008; 177: 19–26.
7. Tashkin DP, Celli B, Senn S et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 1543–54.
8. Хроническая обструктивная болезнь легких. (Федеральная программа). Практическое руководство для врачей. Под ред. А.Г.Чучалина. М., 2004.
9. Хроническая обструктивная болезнь легких. Под ред. А.Г.Чучалина. М.: Изд-ий дом «Атмосфера», 2008.
10. van Noord JA, Aumann J-L. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
11. Welte T, Hartman L, Polanowski T et al. Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients. Am J Respir Crit Care Med 2009; 179: A6188.
12. Welte T, Miravitlles M, Peterson S et al. Budesonide/formoterol added to tiotropium improves the management of COPD patients. Am J Respir Crit Care Med 2009; 179: A6192.
13. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34 (1): 13–6.
14. Garbe E, LeLorier J, Boivin JF et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722–7.
15. Hubbard RB, Smith CJ, Smeeth L et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002; 166: 1563–6.
16. Suissa S, Baltzan M, Kremer R et al. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169: 83–8.
17. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337: 8–14.
18. Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280: 539–43.
19. Ernst P, Baltzan M, Deschenes J et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168–74.
20. Ernst P, Gonzalez AV, Brassard P et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162–6.
21. Keatings VM, Jatakanon A, Worsdell YM et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542–8.
22. Culpitt SV, Maziak W, Loukidis S et al. Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 1635–9.
23. Loppow D, Schleiss MB, Kanniess F et al. In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med 2001; 95: 115–21.
24. Gan WQ, Man SF, Sin DD. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005; 5: 3.
25. Hattotuwa KL, Gizycki MJ, Ansari TW et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002; 165: 1592–6.
26. Bourbeau J, Christodoulopoulos P, Maltais F et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007; 62: 938–43.
27. Ito K, Ito M, Elliott WM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967–76.
28. Barnes PJ. Role of HDAC2 in the pathophysiology of COPD. Ann Rev Physiol 2008; [Epub Ahead of Print PMD: 18817512].
29. Rabe KF, Timmer W, Sagkriotis A et al. Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD. CHEST 2008; 134: 255–62.
30. Troosters T, Kesten S, Burkhart D, Celli B et al. Effectiveness of Tiotropium as First Maintenance Drug in Patients with COPD. Secondary Analysis of the UPLIFT Trial. Am J Respir Crit Care Med 2009; 179: A2467.
31. Лещенко И.В. Ключевые вопросы ранней терапии хронической обструктивной болезни легких. Consilium Medicum 2008; 10 (10): 46–50.